News

• An update to our trademark report is now available

    To access it, please log in to your account and go to the "Trademark" section. If you're not registered yet, simply sign up with your reference number.
  
  
  

  11/06/2025

• Henkel Targets ‘HENCGLUE’ in Transatlantic Trademark Clash

  
  
  
  On 6 June, German manufacturing powerhouse Henkel lodged a formal opposition in the US against Hong Kong-based Polaris Trading over the trademark application ‘HENCGLUE’, which was filed for a suite of industrial adhesives. Henkel, a global leader in personal care, laundry, and adhesives—boasting revenues of €21.6 billion in 2024—argues the mark is confusingly similar to its own well-established ‘HENKEL’ brand. With a diverse brand stable that includes Persil, Pril, Loctite, and UniBond, the Düsseldorf-headquartered firm contends that the proposed mark could dilute its identity and cause consumer confusion across its expansive industrial portfolio. The dispute underscores Henkel’s strategic vigilance in safeguarding its brand equity as it maintains a strong international footprint across multiple sectors. Following visualisation shows detail info on opposed trademark.
  
  

  
  

  09/06/2025

• Novartis Secures Trademark Victory Amid Strategic Growth and Global Focus

  
  
  
  In 2025, Novartis AG, the Swiss pharmaceutical titan, reinforced its position as a global brand powerhouse through a successful trademark opposition against a German applicant seeking to register the identical “novartis” name. The EUIPO ruled entirely in favour of Novartis, rejecting the application, citing serious risk of brand dilution and strong evidence of the company's established reputation. This legal triumph comes as Novartis, now laser-focused on branded pharmaceuticals following the spin-off of its generics unit Sandoz, reported a robust$50.3 billion in global revenue for 2024. The U.S. and Europe remain its financial strongholds, with top-performing drugs such as Entresto and Cosentyx bolstering returns. The company continues to invest heavily in innovation, dedicating one-fifth of its revenue to R&D, and advancing next-generation therapies like Piqray. Notably, Novartis is increasingly integrating artificial intelligence into its pipeline, signalling a tech-forward future for the firm.
  
  

  
  

  04/06/2025